John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin in relapsed or refractory classic hodgkin lymphoma (R/R cHL)
John Kuruvilla, MD on the Specific of the Phase II Study of Pembrolizumab vs. Brentuximab #ASCO2020 @ClevelandClinic #ASCO
